Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
TSH BiopharmROCO:8432 84 EBITDA Margin % is 15.02% as of Dec. 2025, which is 9% below its 10-year median of 16.54. GuruFocus rates ROCO:8432 with a GF Score™ of 84/100 and a GF Value™ of NT$78.92 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 961 Drug Manufacturers companies, TSH Biopharm ranks better than 67.12% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. TSH Biopharm's EBITDA for the
three
months ended in Dec. 2025 was NT$54 Mil. TSH Biopharm's Revenue for the
three
months ended in Dec. 2025 was NT$358 Mil. Therefore, TSH Biopharm's EBITDA margin for the quarter that ended in Dec. 2025 was 15.02%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
TSH Biopharm EBITDA Margin % Related Terms
TSH Biopharm EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for TSH Biopharm's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:8432 vs ZTS, UTHR: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, TSH Biopharm's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TSH Biopharm EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, TSH Biopharm's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where TSH Biopharm's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSH Biopharm (ROCO:8432) has a EBITDA Margin % of 15.02% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on TSH Biopharm and its competitors. This is near median its historical median of 16.54. Over the past decade, TSH Biopharm's EBITDA Margin % has ranged from 7.63 to 22.27. According to the industry distribution chart, TSH Biopharm ranks #316 out of 961 companies in the Drug Manufacturers industry, placing it in the top 32.9%.
Is TSH Biopharm's EBITDA Margin % too high?
TSH Biopharm's current EBITDA Margin % of 15.02% is near median its 10-year median of 16.54. Over the past 10 years, this metric has ranged from a low of 7.63 to a high of 22.27. The Drug Manufacturers industry median EBITDA Margin % is 12.49. TSH Biopharm's value of 15.02% is 20.3% above this industry median. Based on the distribution chart, TSH Biopharm ranks #316 out of 961 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, TSH Biopharm has a GF Score™ of 84/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does TSH Biopharm's EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, TSH Biopharm ranks #316 out of 961 companies for EBITDA Margin %. This puts TSH Biopharm in the upper half of its industry. The industry median EBITDA Margin % is 12.49. TSH Biopharm's value of 15.02% is 20.3% above this benchmark. Historically, TSH Biopharm's own EBITDA Margin % has ranged from 7.63 to 22.27 over the past decade. While the company's 10-year median is 16.54 vs. the industry median of 12.49, TSH Biopharm has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.49, based on 961 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. TSH Biopharm's current EBITDA Margin % of 15.02% is 20.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on TSH Biopharm and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TSH Biopharm's current EBITDA Margin % is 15.02%, which is near median its own 10-year median of 16.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TSH Biopharm stock overvalued right now?
Based on GuruFocus' analysis, TSH Biopharm (ROCO:8432) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$78.92, compared to a current price of NT$50.20 — trading 36.4% below its estimated fair value. The current EBITDA Margin % is 15.02%, which is near median its 10-year median of 16.54 and 20.3% above the Drug Manufacturers industry median of 12.49. TSH Biopharm's overall GF Score™ is 84/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For TSH Biopharm (ROCO:8432), the current EBITDA Margin % is 15.02% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TSH Biopharm (ROCO:8432) Overvalued in 2026?
Based on GuruFocus' analysis, TSH Biopharm stock appears to be undervalued.
The current stock price of NT$50.20 is trading 36.4% below its estimated GF Value™ of NT$78.92.
GuruFocus considers TSH Biopharm to be Significantly Undervalued.
Key valuation signals for ROCO:8432:
EBITDA Margin %: 15.02% (near median its 10-year median of 16.54)
GF Value™: NT$78.92 vs. price of NT$50.20 (36.4% below fair value)
Industry Position: 20.3% above the Drug Manufacturers median (#316 of 961)
No single metric tells the full story. See the ROCO:8432 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TSH Biopharm Corp Ltd is engaged in sale of a variety of pharmaceuticals, chemical drugs and engaged in biotechnology services. The company specializes in the development, manufacture, and marketing of branded drugs for chronic diseases. Key therapeutic areas include cardiovascular, central nervous system, gastroenterology, and severe chronic diseases, alongside precision medicine/genetic testing services .The Company's revenue is earned domestically. It earns majority of its revenue from the sale of Lozenges.
84GF Score
Get the complete analysis for ROCO:8432
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:8432 has been successfully added to your 
